With industry eagerly anticipating readouts from Merck and Moderna’s Phase 3 trial of adjuvant V940 in combination with Keytruda, BioNTech, and Genentech’s global trials for BNT116 for non-small cell lung cancer, we are advancing ever closer to a commercially approved personalized cancer vaccine.

Time: 8:30 AM – 5:40 PM

Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States

Prices: USD 2599.00 – USD 5097.00

Speakers: Alan Rigby, Chief Executive Officer, Epitopea, Ananta Paine, Senior Associate, Guide Point Insights, and more